Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 11, 2010

Roche Diagnostics Purchases Microarray Instrument and Accessory Assets from BioMicro Systems

  • Roche Diagnostics purchased assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow. These assets include the NimbleGen Hybridization Systems (both 4- and 12-bay models) and array accessories covering all mixers designed for the Roche NimbleGen high-density microarray portfolio.

    With the purchase of these assets, Roche Diagnostics will transfer the manufacturing capabilities for the above products to an in-house manufacturing facility. “The acquired products are integral to the high-quality data the NimbleGen array workflow provides researchers worldwide,” points out Andreas Görtz, vp of marketing at Roche NimbleGen.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »